Esperion Therapeutics, Inc. (ESPR) Expected to Announce Earnings of -$1.67 Per Share
Equities analysts predict that Esperion Therapeutics, Inc. (NASDAQ:ESPR) will announce earnings of ($1.67) per share for the current quarter, Zacks reports. Zero analysts have issued estimates for Esperion Therapeutics’ earnings. The highest EPS estimate is ($1.38) and the lowest is ($1.83). Esperion Therapeutics posted earnings of ($0.62) per share in the same quarter last year, which would indicate a negative year-over-year growth rate of 169.4%. The firm is expected to report its next quarterly earnings results after the market closes on Tuesday, August 8th.
According to Zacks, analysts expect that Esperion Therapeutics will report full-year earnings of ($6.80) per share for the current financial year, with EPS estimates ranging from ($7.40) to ($6.00). For the next year, analysts anticipate that the business will post earnings of ($5.38) per share, with EPS estimates ranging from ($6.43) to ($4.38). Zacks Investment Research’s earnings per share averages are a mean average based on a survey of sell-side research analysts that follow Esperion Therapeutics.
Esperion Therapeutics (NASDAQ:ESPR) last announced its quarterly earnings results on Tuesday, August 8th. The biopharmaceutical company reported ($1.92) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.62) by $0.30. During the same quarter in the previous year, the firm earned ($0.62) EPS.
Several research firms have recently issued reports on ESPR. Jefferies Group LLC upgraded shares of Esperion Therapeutics from a “hold” rating to a “buy” rating in a report on Tuesday. Needham & Company LLC upped their price objective on shares of Esperion Therapeutics from $58.00 to $72.00 and gave the company a “positive” rating in a report on Tuesday. BidaskClub downgraded shares of Esperion Therapeutics from a “strong-buy” rating to a “buy” rating in a report on Friday. UBS AG restated a “buy” rating and set a $57.00 price objective (up previously from $52.00) on shares of Esperion Therapeutics in a report on Tuesday, June 27th. Finally, Stifel Nicolaus restated a “buy” rating and set a $60.00 price objective (up previously from $45.00) on shares of Esperion Therapeutics in a report on Monday, June 26th. Seven research analysts have rated the stock with a hold rating and nine have assigned a buy rating to the stock. The stock presently has an average rating of “Buy” and an average price target of $39.16.
A number of large investors have recently modified their holdings of the stock. Teachers Advisors LLC raised its stake in shares of Esperion Therapeutics by 56.7% in the fourth quarter. Teachers Advisors LLC now owns 33,502 shares of the biopharmaceutical company’s stock worth $419,000 after buying an additional 12,122 shares in the last quarter. Bank of Montreal Can raised its stake in Esperion Therapeutics by 1,006.7% in the first quarter. Bank of Montreal Can now owns 6,596 shares of the biopharmaceutical company’s stock valued at $233,000 after buying an additional 6,000 shares in the last quarter. Nationwide Fund Advisors raised its stake in Esperion Therapeutics by 2.4% in the first quarter. Nationwide Fund Advisors now owns 39,286 shares of the biopharmaceutical company’s stock valued at $1,387,000 after buying an additional 921 shares in the last quarter. Russell Investments Group Ltd. bought a new stake in Esperion Therapeutics during the first quarter valued at approximately $961,000. Finally, Wells Fargo & Company MN raised its stake in Esperion Therapeutics by 39.4% in the first quarter. Wells Fargo & Company MN now owns 11,602 shares of the biopharmaceutical company’s stock valued at $410,000 after buying an additional 3,282 shares in the last quarter. Hedge funds and other institutional investors own 85.20% of the company’s stock.
Shares of Esperion Therapeutics (NASDAQ ESPR) traded up 15.41% during mid-day trading on Tuesday, hitting $52.13. 4,151,267 shares of the stock were exchanged. The stock’s 50 day moving average is $45.38 and its 200-day moving average is $33.91. The stock’s market cap is $1.18 billion. Esperion Therapeutics has a 12 month low of $9.40 and a 12 month high of $57.38.
About Esperion Therapeutics
Esperion Therapeutics, Inc is a lipid management company. The Company is a late-stage pharmaceutical company focused on developing and commercializing once-daily, oral therapies for the treatment of patients with elevated low-density lipoprotein cholesterol (LDL-C). With a targeted mechanism of action, bempedoic acid, the Company’s lead product candidate, is an orally available, once-daily adenosine triphosphate (ATP)-citrate lyase (ACL) inhibitor that reduces cholesterol biosynthesis and lowers elevated levels of LDL-C by up-regulating the LDL receptor, but with reduced potential for muscle-related side effects.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Esperion Therapeutics Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Esperion Therapeutics Inc. and related companies with MarketBeat.com's FREE daily email newsletter.